Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

by B2i | Jun 2, 2025 | Press Releases

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving...

Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

by B2i | May 14, 2025 | Press Releases

Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant...

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

by B2i | May 1, 2025 | Press Releases

JUPITER, Fla., May 01, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic to Present at World Vaccine Congress | Washington

by B2i | Apr 16, 2025 | Press Releases

JUPITER, Fla., April 16, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to...

Dyadic Reports 2024 Year-End Financial Results and Business Updates

by B2i | Mar 26, 2025 | Press Releases

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and...